Lenalidomide Wockhardt Uk (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, changing its activity. This leads to the degradation of specific transcription factors, resulting in anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that suppress malignant plasma cells and other cancerous blood cells.

The dosage of Lenalidomide Wockhardt Uk is determined by the prescribing clinician based on the specific indication, patient characteristics and treatment protocol. The prescriber sets the exact dose and schedule according to approved guidelines and individual patient needs.

Lenalidomide is classified as potentially harmful to a developing fetus and is contraindicated in pregnancy. Women of childbearing potential must use effective contraception. Safety during breastfeeding has not been established, and breastfeeding is generally not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide is a derivative of thalidomide with enhanced immunomodulatory activity and a more favorable safety profile. It generally offers greater efficacy in multiple myeloma and reduced incidence of peripheral neuropathy compared with thalidomide, though both require careful monitoring for hematologic toxicity.

Lenalidomide tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Lenalidomide Wockhardt Uk is taken orally as a tablet, usually once daily on a prescribed schedule. It is typically swallowed with water and may be taken with or without food, depending on the prescriber’s instructions.

The most serious risks include severe neutropenia and thrombocytopenia, which can lead to infections or bleeding, and the potential for venous thromboembolism. Rarely, secondary primary malignancies may develop. Patients should be monitored closely for these events.

Lenalidomide is contraindicated in patients with known hypersensitivity to the drug or its excipients, in pregnant women, and in individuals who cannot adhere to required contraception. Caution is also advised for patients with severe renal impairment or uncontrolled infections.